Edesa Biotech Inc (EDSA) COM NPV
Edesa Biotech, Inc. is a Canada-based biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. It is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. It is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.